Vaxcyte, Inc. (PCVX)
After hours:
| Previous close | 60.06 |
| Open | 60.32 |
| Bid | 60.62 x 300 |
| Ask | 60.74 x 300 |
| Day's range | 59.41 - 60.94 |
| 52-week range | 42.98 - 82.04 |
| Volume | |
| Avg. volume | 865,760 |
| Market cap | 6.604B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.14 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 103.29 |
GlobeNewswireVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media se
GuruFocus.comSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
Full Year Earnings Reveal Strong Revenue Growth but Operational Challenges Persist
GuruFocus.comInsider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 Shares
Andrew Guggenhime, President and Chief Financial Officer of Vaxcyte Inc (NASDAQ:PCVX), has sold 8,000 shares of the company on March 18, 2024, according to a recent SEC filing.
